Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study

Inclusion Criteria: * Patient ≥ 18 years old, * Hospitalized in intensive care, intubated and ventilated * With COVID-19 pneumonia confirmed by Rt-PCR, * Having as specific treatment hydroxychloroquine, whatever the dosage regimen * Having had the monitoring of the residual concentrations carried out by the Pharmacokinetics and Toxicology Laboratory of the Federative Institute of Biology of the Toulouse University Hospital the clinical Pharmacology and Toxicology laboratory of the Toulouse University Hospital * Person affiliated to a social security scheme or equivalent Exclusion Criteria: * Minor patients * Patients refusing to participate in the study * Person participating in another research including an exclusion period still in progress. * Contraindications to hydroxychloroquine: pre-existing retinopathy, known hypersensitivity to 4-aminoquinolines, hemolytic anemia, porphyria, G6PD deficiency, myasthenia gravis, association with citalopram, escitalopram, hydroxyzine, domperidone and piperaquine * Patients undergoing treatment with medicines known to prolong the QT interval or likely to induce a cardiac arrhythmia such as for example anti-arrhythmics of class IA and III, tricyclic antidepressants and certain anti-infectives (in particular antibiotics of the family of macrolides and fluoroquinolones as well as trimethoprim-sulfamethoxazole). * Pregnant or breastfeeding women